ACTA2 Products

ACTA2 Full Name

actin, alpha 2, smooth muscle, aorta

ACTA2 Introduction

ACTA2 (actin, alpha 2, smooth muscle, aorta) encodes smooth muscle α-actin (SMα-actin), a core cytoskeletal protein that defines the contractile identity of vascular smooth muscle cells (VSMCs). For researchers and clinicians working on aortic disease, ACTA2 represents a critical pain point: it is one of the most frequently mutated genes in inherited thoracic aortic aneurysm and dissection, yet its pathogenic mechanisms extend far beyond simple loss of contractility. Emerging single-cell and functional genomics studies have shown that ACTA2 is not merely a structural marker, but a key regulator of smooth muscle cell state. Variants in ACTA2 disrupt cytoskeletal integrity and force transmission, predisposing the aortic wall to mechanical failure under physiological stress. This makes ACTA2 a high-value target for mechanistic studies, biomarker discovery, and therapeutic intervention in aortopathy and related vascular disorders.

Functionally, ACTA2 plays a central role in maintaining the contractile phenotype of VSMCs, enabling coordinated actin–myosin interactions and stable adhesion to the extracellular matrix. Loss-of-function or dominant-negative ACTA2 variants drive a pathological phenotypic switch from a quiescent, contractile state toward a synthetic and proliferative program. Recent single-nucleus and single-cell transcriptomic analyses have revealed that ACTA2 mutations give rise to distinct pro-proliferative VSMC subpopulations accompanied by widespread transcriptional reprogramming. These cells show altered expression of cytoskeletal genes, integrins, and adhesion molecules, consistent with impaired force sensing and matrix attachment. At the molecular level, pathogenic variants such as R149C reduce SMα-actin levels, trigger compensatory upregulation of alternative actin isoforms, and markedly decrease integrin recruitment at cell–matrix adhesions, ultimately weakening cellular contractility and vessel wall stability.

Clinically, ACTA2 is strongly linked to a spectrum of vascular and systemic diseases, including familial thoracic aortic aneurysm and dissection, bicuspid aortic valve–associated aortopathy, early-onset stroke, coronary artery disease, and multisystemic smooth muscle dysfunction syndrome. Its relevance has been reinforced by multi-omics studies showing differential ACTA2 expression across contractile, proliferative, and inflammatory smooth muscle cell populations in diseased aortas. Importantly, ACTA2 has moved beyond being a diagnostic gene toward a potential therapeutic target: recent preclinical work demonstrates that precise genomic correction of pathogenic ACTA2 variants can prevent smooth muscle phenotypic switching, restore vascular contractility, and even reverse multi-organ smooth muscle dysfunction in vivo. Together, these findings position ACTA2 at the intersection of disease mechanism, translational research, and next-generation therapies, addressing a critical unmet need in the management of inherited and sporadic aortic disease.

Alternate Names for ACTA2

ACTA2
actin, alpha 2, smooth muscle, aorta
AAT6
ACTSA
MYMY5
actin, aortic smooth muscle
alpha-cardiac actin
cell growth-inhibiting gene 46 protein

• ACTA2 Antibodies
• ACTA2 ELISA Kits
• ACTA2 Antigens

• 1.Pepin ME, et al.; Dysregulated smooth muscle cell proliferation and gene expression underlie ACTA2 variant-associated aortopathy. Am J Physiol Heart Circ Physiol. 2025, 329(5):H1072-H1079.
  2.Ojha KR, et al.; Smooth Muscle-Alpha Actin R149C Pathogenic Variant Downregulates Integrin Recruitment at Cell-Matrix Adhesions and Decreases Cellular Contractility. Int J Mol Sci. 2023, 24(11):9616.